Mresvia (Single-Stranded 5' Capped Mrna Encoding The Respiratory Syncytial Virus Glycoprotein F Stabilized In)

mRNA-1345 is a single‑stranded, 5' capped messenger RNA that encodes a stabilized form of the RSV F glycoprotein. After intramuscular injection, host cells translate the mRNA into the viral protein, which is then recognized by the immune system, leading to the production of neutralising antibodies and cellular immunity that protect against RSV.

The dose of Mresvia is determined by the prescribing healthcare professional based on the patient’s age, health status, and local immunisation guidelines. The prescriber will select the appropriate volume and schedule for each individual.

Safety data for Mresvia in pregnant or breastfeeding individuals are limited. Healthcare providers should weigh the potential benefits against any unknown risks and discuss the decision with the patient. Consultation with a specialist is recommended before vaccination in these populations.

To order Mresvia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. The team then replies with pricing, availability, cold‑chain shipping details, and any necessary import documentation.

Mresvia uses an mRNA platform that delivers the RSV F antigen directly to host cells, whereas many existing RSV vaccines rely on protein subunits or live‑attenuated viruses. The mRNA approach can induce both strong antibody and T‑cell responses and may offer manufacturing flexibility, but comparative effectiveness depends on clinical trial data and population specifics.

Mresvia must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If temperature excursions occur, follow the product’s stability guidelines before use.

Mresvia is administered as a single intramuscular injection, typically into the deltoid muscle. The injection is performed by a qualified healthcare professional using aseptic technique. The exact volume and site are determined by the prescriber according to approved labeling.

The most serious risks include severe allergic reactions such as anaphylaxis, myocarditis or pericarditis, and rare neurological events like Guillain‑Barré syndrome. Patients should be observed for at least 15 minutes after vaccination, and any signs of a serious reaction require immediate medical attention.

Mresvia should not be given to individuals with a known severe allergy to any component of the vaccine. It is also contraindicated in patients who have experienced a serious immediate hypersensitivity reaction to a previous dose of the same vaccine. Clinicians should assess each patient’s medical history before administration.